Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice

First Page		Document Content
Anatomy Endothelial progenitor cell Vascular endothelial growth factor Angiogenesis Rivaroxaban Direct Xa inhibitor Stromal cell-derived factor-1 Diabetes management Endothelium Biology Angiology Medicine		Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice Add to Reading List Source URL: www.cardiab.com Download Document from Source Website File Size: 1,62 MB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qfnw - View Document
	4th Joint EFLM – UEMS Congress European Union of Medical Specialists Section of Laboratory Medicine/Medical Biopathology Laboratory medicine at the clinical interface DocID: 1pTLL - View Document
	SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Venous Thromboembolism (VTE) Prevention Following Surgery Pharmaceutical Services Department of Health and Community Serv DocID: 1p0MX - View Document
	Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice DocID: 1fSQN - View Document
	To: General Practitioners Community Pharmacists Non-Medical Prescribers 18 FebruaryDirectorate of Integrated Care DocID: ZNvr - View Document